Cancer patients with SPEN mutation had distinct tumor immune signatures, higher TMB and MSI and more MMR mutant genes, and further explain an underlying mechanism of the predictive value of SPEN mutation on the immunotherapy efficacy. The gene discussed is MRC1; the disease is cancer.